KBC Group NV Increases Stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

KBC Group NV boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 3.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 243,938 shares of the specialty pharmaceutical company's stock after acquiring an additional 7,620 shares during the period. KBC Group NV owned 0.40% of Jazz Pharmaceuticals worth $30,285,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $25,000. Bank of New York Mellon Corp raised its stake in Jazz Pharmaceuticals by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after buying an additional 24,481 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Jazz Pharmaceuticals by 24.2% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 9,588 shares of the specialty pharmaceutical company's stock valued at $1,181,000 after buying an additional 1,867 shares during the period. Proficio Capital Partners LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $4,762,000. Finally, Jones Financial Companies Lllp boosted its position in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Down 0.4%

Jazz Pharmaceuticals stock traded down $0.48 during midday trading on Thursday, hitting $109.45. 327,049 shares of the stock were exchanged, compared to its average volume of 826,821. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. The business's 50-day moving average price is $108.98 and its 200-day moving average price is $119.28. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of 14.59, a price-to-earnings-growth ratio of 4.72 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. Jazz Pharmaceuticals's quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.68 EPS. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the sale, the chief executive officer owned 439,307 shares of the company's stock, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Seamus Mulligan purchased 100,000 shares of the firm's stock in a transaction dated Friday, May 9th. The shares were bought at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the purchase, the director owned 100,000 shares in the company, valued at $9,826,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 2,500 shares of company stock valued at $277,930. 4.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on JAZZ. Royal Bank Of Canada lowered their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Piper Sandler restated an "overweight" rating and set a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Morgan Stanley decreased their target price on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.